Brief: OncoCyte Announces Unanimous Recommendation From Advisory Panel For DetermaRx To CMS
07/09/2022 13:13
Sept 7 (Reuters) - OncoCyte Corp OCX.O :
* ONCOCYTE ANNOUNCES UNANIMOUS RECOMMENDATION FROM THE
ADVISORY
PANEL FOR CLINICAL DIAGNOSTIC LABORATORY TESTS ON DETERMARX TO
CMS
Source text for Eikon: ID:nGNX235LCQ
Further company coverage: OCX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insight Molecular Diagnostics
See all newsBrief: Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a share - Earnings Preview
Insight Molecular Diagnostics Q1 loss narrows as costs drop
Brief: Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission